Johannes Ramaekers
Professor of Psychopharmacology
Data updated
Research Footprint
Johannes Ramaekers appears in 65 tracked papers (2005–2026), most studied alongside Psilocybin, MDMA and Ayahuasca, across Healthy Volunteers, Depressive Disorders and Anxiety Disorders.
Most-cited paper: Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin (258 citations).
Frequent co-authors: Nathalie Mason, Kim Kuypers and Jan Reckweg.
Publication Landscape
How the 65 papers Blossom tracks for Johannes Ramaekers line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Johannes Ramaekers's publishing grown?
SourcedTracked papers by publication year; 4 earlier papers published before 2012. Click a year for the running total.
Don't read as total output: only the 65 of 65 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Johannes Ramaekers publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Johannes Ramaekers publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Johannes Ramaekers is a Professor of Psychopharmacology and Behavioral Toxicology at Maastricht University. His research focuses on how various drugs, including psychedelics and cannabis, affect cognitive functions such as memory, attention, and creativity. He is a prominent figure in behavioral toxicology and has published extensively on the therapeutic and performance-related impacts of psychoactive compounds.
Key Impact
Leading expert in behavioral toxicology and the impact of psychoactive substances on human performance and cognition.
Collaboration Network
74 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Johannes Ramaekers's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Johannes Ramaekers is associated with.
Maastricht University
academicProfessor of Psychopharmacology
While Maastricht University may not have a single dedicated psychedelic research group, various researchers at the university are investigating the effects of psychedelics. Early research exploring psychedelics at Maastricht focused on the dangers of MDMA. Now, research into the effects of microdosing is being led by Dr Kim Kuypers. Other research ongoing at the university is investigating cannabis as well as novel psychoactive substances (NPS). Maastricht is collaborating on research with the Beckley Foundation as well as Silo Pharma.
View stakeholder →GH Research
Public BiotechGH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Dublin, Ireland, developing novel mebufotenin (5-MeO-DMT) therapeutics for treatment-resistant depression, bipolar II disorder, and postpartum depression. Its lead asset GH001 — an inhaled mebufotenin formulation — met the primary endpoint of its Phase 2b TRD trial in February 2025 with striking results: -15.5 point MADRS reduction vs placebo (p<0.0001) and 57.7% remission vs 0%. With a single-day dosing paradigm requiring no structured psychotherapy, GH001 is positioned as a differentiated asset; Phase 3 global initiation is planned for 2026 following FDA clinical hold lift. GH002 (IV mebufotenin) completed Phase 1 in healthy volunteers.
View stakeholder →